Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12607000134426
Ethics application status
Approved
Date submitted
13/02/2007
Date registered
19/02/2007
Date last updated
14/09/2012
Type of registration
Prospectively registered

Titles & IDs
Public title
N-acetylcysteine in Unipolar depression
Scientific title
The Efficacy of N-acetylcysteine as an Adjunctive Treatment to improving depression in patients with Unipolar Depression: A Double-blind, Randomised, Placebo-controlled Trial
Secondary ID [1] 281088 0
NAC and UD
Secondary ID [2] 281230 0
NAC and UD
Universal Trial Number (UTN)
Trial acronym
N-acetylcysteine
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Unipolar depression 1627 0
Condition category
Condition code
Mental Health 1735 1735 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
N-acetylcysteine will be administered 2mg/day in two 500mg capsules to be taken twice daily for a duration of 8 weeks. Patients will be randomly assigned to N-acetylcysteine.
Intervention code [1] 1596 0
Treatment: Drugs
Comparator / control treatment
Placebo will be administered 2mg/day in two 500mg capsules to be taken twice daily for a duration of 8 weeks. Patients will be randomly assigned to placebo group.
Control group
Placebo

Outcomes
Primary outcome [1] 2412 0
The Montgomery Asberg depression Rating Scale (MADRS)
Timepoint [1] 2412 0
The scale will be administered at weeks 2, 4, 6 and 8 post-baseline intervals
Secondary outcome [1] 4188 0
The secondary outcomes include Clinical Global Impression - Improvement (CGI-I) and Severity (CGI-S), Global Assessment of Functioning Scale (GAF), Social and Occupational Functioning Assessment Scale (SOFAS), SLICE LIFE/LIFE RIFT, Quality of life Enjoyment & Satisfaction Questionnaire (Q-Les-Q).
Timepoint [1] 4188 0
These scales will be administered at weeks 2, 4, 6, and 8 post-baseline intervals.

Eligibility
Key inclusion criteria
Have capacity to consent, meet Diagnostic and Statistical Manual for Mental Disorders, Fourth edition, revision (DSM-IV-TR) criteria for major depressive disorder, have single episode or recurrent, achieve score of 18 or over on the MADRS at the time of trial entry, patients on antidepressant therapy need to have been on the same treatment for one month prior to randomisation, and if female of child bearing age and sexually active need to utilise effective contraception.
Minimum age
18 Years
Maximum age
Not stated
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The exclusion criteria include individuals with concurrent diagnosis of bipolar I or II disorder, bipolar disorder not otherwise specified, electroconvulsive therapy for current depressive episode, concurrent primary diagnosis of a personality disorder, known or suspected clinically unstable systemic medical disorder, elderly subjects with respiratory insufficiency, recent gastrointestinal ulcers, pregnancy or breastfeeding, current use of greater than 500mg of NAC/day, 200mg of selenium or 500 IU of vitamin E/day, and history of anaphylactic reaction to NAC or any component of the preparation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Treatment were randomly assigned into pack numbers by an individual independent of participant recruitment. Trial clinicians recruited participants and allocated them sequential pack numbers thereby adhering to double blind procedures.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Treatments were allocated into pack numbers by a simple coin tossing method. Participants were then recruited and allocated sequential pack numbers.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Neither investigators nor patients are aware of which treatment aim the patients have been allocated. The blindness will be remained until the completion of the study.
Phase
Phase 3 / Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/05/2007
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
120
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1885 0
Other
Name [1] 1885 0
Stanley Medical Research Institute
Country [1] 1885 0
United States of America
Primary sponsor type
Other
Name
Mental Health Research Institute
Address
Oak Street, Parkville
Country
Australia
Secondary sponsor category [1] 1699 0
None
Name [1] 1699 0
N/A
Address [1] 1699 0
Country [1] 1699 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 3508 0
Barwon Health
Ethics committee address [1] 3508 0
Ethics committee country [1] 3508 0
Australia
Date submitted for ethics approval [1] 3508 0
29/05/2007
Approval date [1] 3508 0
12/06/2007
Ethics approval number [1] 3508 0
07/24
Ethics committee name [2] 3509 0
Royal North Shore Hospital,
Ethics committee address [2] 3509 0
Ethics committee country [2] 3509 0
Australia
Date submitted for ethics approval [2] 3509 0
Approval date [2] 3509 0
18/09/2007
Ethics approval number [2] 3509 0
0708-147M
Ethics committee name [3] 4415 0
Bendigo Health Care Group
Ethics committee address [3] 4415 0
Ethics committee country [3] 4415 0
Australia
Date submitted for ethics approval [3] 4415 0
17/07/2007
Approval date [3] 4415 0
23/11/2007
Ethics approval number [3] 4415 0
9/2007
Ethics committee name [4] 5110 0
Mental Health Research Institute
Ethics committee address [4] 5110 0
Ethics committee country [4] 5110 0
Australia
Date submitted for ethics approval [4] 5110 0
07/08/2007
Approval date [4] 5110 0
13/11/2007
Ethics approval number [4] 5110 0
07/24_T1

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 27530 0
Address 27530 0
Country 27530 0
Phone 27530 0
Fax 27530 0
Email 27530 0
Contact person for public queries
Name 10785 0
Professor Michael Berk
Address 10785 0
Mental Health, Swanston Centre
PO Box 281 Geelong, VIC, 3220
Country 10785 0
Australia
Phone 10785 0
03 5226 7450
Fax 10785 0
03 5226 7436
Email 10785 0
[email protected]
Contact person for scientific queries
Name 1713 0
Professor Michael Berk
Address 1713 0
Mental Health, Swanston Centre
PO Box 281 Geelong, VIC 3220
Country 1713 0
Australia
Phone 1713 0
03 5226 7450
Fax 1713 0
03 5226 7436
Email 1713 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseAdjunctive N-acetylcysteine in depression: Exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor.2017https://dx.doi.org/10.1017/neu.2017.2
EmbaseThe Impact of N-acetylcysteine on Major Depression: Qualitative Observation and Mixed Methods Analysis of Participant Change during a 12-week Randomised Controlled Trial.2023https://dx.doi.org/10.9758/CPN.2023.21.2.320
N.B. These documents automatically identified may not have been verified by the study sponsor.